About Singulex
Singulex is a Healthcare company based in Alameda (United States) founded in 1997. Single-molecule counting technology is developed for cardiovascular biomarker detection. Singulex has raised $140.94 million across 16 funding rounds from investors including SVB, Grifols and HHS. The company has 236 employees. Its chief executive, as recorded, is Guido Baechler. Singulex offers products and services including Sgx Clarity System. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include Metabolon, Maze Therapeutics and Seer; 3 of its 3 listed competitors have raised funding.
Company details
Singulex was founded in 1997 in Alameda, United States, and operates in the biotechnology sector focused on cardiodiagnostics. Single-molecule counting instruments and biomarker research are developed and commercialized for cardiovascular monitoring. Immunoassay solutions, lab testing services, and the Clarity System for automated in vitro analysis are provided to support disease treatment, health management, and therapeutic development.
- Headquarters Alameda, United States
- Employees 236
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website singulex.com
- Social LinkedIn X
- Total Equity Funding$140.94M (USD)
in 16 rounds
- Latest Funding Round$50M (USD), Debt – Conventional
Apr 2017
- InvestorsSVB
& 10 more
- Employee Count236
Products & Services of Singulex
Singulex offers a comprehensive portfolio of products and services, including Sgx Clarity System.
Ultra-sensitive platform for detecting low-abundance biomarkers in healthcare
Funding Insights of Singulex
Singulex has successfully raised a total of $140.94M across 16 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $140.94M
- Total Rounds 16
- Last Round Debt – Conventional — $50M
- First Round $1M
(Oct 2002)
- Investors Count 11
Latest 10 of 16 funding rounds of Singulex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $50M | Debt – Conventional | – | – | |
| May 2016 | $50M | Series G | – | – | |
| Sep 2013 | $40M | Debt – Conventional | – | – | |
| Jun 2013 | $15M | Series F | – | – | |
| Mar 2012 | $15.34M | Series F | – | Orbimed, Prolog Ventures | – |
| Aug 2011 | $9.65M | Series E | – | – | – |
| Apr 2011 | $99,406 | Grant | – | – | |
| Apr 2011 | $99,406 | Grant | – | – | |
| Jan 2009 | $19M | Series E | – | Orbimed, JAFCO Group | – |
| Jun 2007 | $19.1M | Series D | – | Orbimed |
11 investors in total: 11 institutional.
Investors in Singulex
Singulex has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Grifols and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Health-focused venture capital investments are made in US sectors. | prologventures.com | Newark, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity investment firm | advantagecap.com | New Orleans, United States | ||
Multiple sectors are invested in by this private equity firm. | gecapital.ca | |||
Plasma-derived therapies are developed to treat multiple diseases. | 1909 | grifols.com | Barcelona, Spain | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Buyouts are targeted through venture capital and private equity investments. | jafco.co.jp | Minato City, Japan | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Singulex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Singulex
1 people are tracked at Singulex (1 in leadership); the tracked headcount is 236.
| Name | Role | Group |
|---|---|---|
Guido Baechler | CEO & President | Leadership |
Complete people profiles for Singulex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Singulex
3 dated milestones of Singulex across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Singulex is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Debt – Conventional, of $50.0M.
Competitors of Singulex
Singulex has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Maze Therapeutics and Seer.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. |
Detailed competitors of Singulex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Singulex
The website of Singulex (singulex.com) receives about 1.3K visits a month and ranks #13,700,698 among all websites worldwide, #8,480 in Biotechnology and Pharmaceuticals.
- Monthly visits1.3K
▲ 12.6% vs previous month
- Global rank#13,700,698
among all websites
- Category rank#8,480
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.1
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Singulex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| idsplc.com | 100% | 5.1K | #4,586,165 | View details | |
drugtestsystems.com | drugtestsystems.com | 37% | – | ||
| quanterix.com | 36% | 46K | #672,404 | View details | |
| uscnk.com | 36% | #7,145,017 | View details | ||
| clu-in.org | 25% | #1,307,262 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Singulex (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Singulex
Complete news archive for Singulex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Singulex
Singulex was founded in 1997 and raised its 1st funding round 5 years after it was founded.
Singulex is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Guido Baechler is the CEO of Singulex, as recorded in our data.
Singulex is a funded company, having raised a total of $140.94M across 16 funding rounds to date. The company's 1st funding round was a Series D of $19.1M, raised on Oct 2002.
Singulex has 236 employees.
Singulex was founded in 1997 in Alameda, United States, and operates in the biotechnology sector focused on cardiodiagnostics. Single-molecule counting instruments and biomarker research are developed and commercialized for cardiovascular monitoring. Immunoassay solutions, lab testing services, and the Clarity System for automated in vitro analysis are provided to support disease treatment, health management, and therapeutic development.
Singulex's top competitors include Maze Therapeutics, Metabolon and Seer.
Singulex offers Sgx Clarity System.
Singulex has 11 investors. Key investors include SVB, Grifols, HHS, Orbimed, and Western Alliance Bank.